Colistin regained global interest as a consequence of the rising prevalence of multidrug-
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …

Polymyxins, including polymyxin B and polymyxin E (colistin), are now increasingly being
used worldwide to treat patients with multidrug-resistant (MDR) Gram-negative bacterial …

Background Low-income and middle-income countries (LMICs) are under-represented in
reports on the burden of antimicrobial resistance. We aimed to quantify the clinical effect of …

Microfluidic platforms have been employed as an effective tool for drug screening and
exhibit the advantages of lower reagent consumption, higher throughput and a higher …

Susceptibility testing of the polymyxins (colistin and polymyxin B) is challenging for clinical
laboratories. The Clinical and Laboratory Standards Institute (CLSI) Antimicrobial …

Colistin is a member of cationic polypeptide antibiotics known as polymyxins. It is widely
used in animal husbandry, plant cultivation, animal and human medicine and is increasingly …

Klebsiella pneumoniae is a rod-shaped, encapsulated, Gram-negative bacteria associated
with multiple nosocomial infections. Multidrug-resistant (MDR) K. pneumoniae strains have …

Multidrug-resistant Acinetobacter baumannii infection has recently emerged as a worldwide
clinical problem, and colistin is increasingly being used as a last-resort therapy. Despite its …

Antibiotics have become the corner stone of modern medicine. However, our society is
currently facing one of the greatest challenges of its time: the emergence of antimicrobial …

Background The burden of antibiotic resistant infection is mainly felt in low-to-middle income
countries, where the rate of antimicrobial resistance is largely under-surveyed and under …